Partnering and Licensing at Genzyme

RDP58

RDP58 (delmitide) is a clinical-stage, minimally-absorbed, rationally-designed D-amino acid decapeptide with established anti-inflammatory properties. Proof of concept for this product opportunity has been demonstrated in models of inflammatory bowel disease (IBD), and the potential also exists to expand its use into other therapeutic areas characterized by inflammation such as arthritis, asthma and interstitial cystitis. To date approximately 400 patients and volunteers have been exposed to RDP58. The development and regulatory pathways for IBD are established and RDP58 is covered by existing patents. Several kilograms of drug substance are also available. Genzyme is now seeking a partner that can develop RDP58 through approval.

For additional information on the RDP58 program, you may download the RDP58 non-confidential summary. More detailed preclinical, clinical, regulatory, and intellectual property information is available after execution of Genzyme’s standard Confidential Disclosure Agreement and establishment of a username and password.

Please complete the CDA and fax to 617-768-6430. If you have any questions, please contact RDP58 Program.

		This area contains information accessible after completion of Genzyme's standard CDA. Please fill in your username and password:
		Username:
		Password:
	If you do not have a password, complete our standard CDA. Forgot your password?

Terms and Conditions of Use | Privacy Policy | © 2002-2009 Genzyme Corporation. All rights reserved.